MDT:NYE-Medtronic plc.

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 99.82

Change

+0.57 (+0.57)%

Market Cap

USD 101.99B

Volume

3.08M

Analyst Target

USD 103.28
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in four operating segments that manufacture and sell device-based medical therapies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+1.98 (+1.78%)

USD 193.47B
SYK Stryker Corporation

+8.33 (+2.38%)

USD 134.32B
BSX Boston Scientific Corp

+0.68 (+1.00%)

USD 99.87B
EW Edwards Lifesciences Corp

+1.73 (+1.85%)

USD 51.24B
ZBH Zimmer Biomet Holdings Inc

+4.74 (+3.71%)

USD 25.43B
STE STERIS plc

+4.00 (+1.81%)

USD 23.00B
SNN Smith & Nephew SNATS Inc

+0.26 (+1.00%)

USD 11.55B
BIO Bio-Rad Laboratories Inc

+9.04 (+2.65%)

USD 9.93B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.67B
PEN Penumbra Inc

+5.51 (+2.49%)

USD 8.60B

ETFs Containing MDT

UMDV:SW iShares US Medical Device.. 10.39 % 0.00 %

+0.07 (+0%)

USD 0.18B
CIB0:XETRA VanEck Bionic Engineering.. 9.95 % 0.00 %

+0.39 (+0%)

USD 6.13M
PINK Simplify Exchange Traded .. 4.65 % 0.00 %

+0.56 (+0%)

USD 0.13B
AIVL WisdomTree Trust - Wisdom.. 3.05 % 0.00 %

+1.32 (+0%)

USD 0.38B
GDVD Principal Active Global D.. 2.46 % 0.00 %

+0.16 (+0%)

USD 0.03B
QUVU 2.33 % 0.00 %

N/A

N/A
DXQ:CA Dynamic Active Enhanced Y.. 2.30 % 0.00 %

+0.07 (+0%)

CAD 0.31B
DVND Touchstone ETF Trust - To.. 2.19 % 0.00 %

+0.41 (+0%)

USD 0.03B
UEDV:LSE SPDR® S&P® U.S. Dividen.. 2.11 % 0.00 %

+0.20 (+0%)

USD 0.03B
UGDV:LSE SPDR® S&P® U.S. Dividen.. 2.11 % 0.00 %

+0.17 (+0%)

USD 0.03B
SNPD 2.11 % 0.00 %

N/A

N/A
PUD.B:CA 1.85 % 0.66 %

N/A

N/A
USDV:SW SPDR® S&P US Dividend Ar.. 1.84 % 0.00 %

+0.06 (+0%)

USD 3.74B
TWAR 1.11 % 0.00 %

N/A

N/A
JIGB JPMorgan Corporate Bond R.. 0.45 % 0.14 %

N/A

USD 0.06B
VCLT Vanguard Long-Term Corpor.. 0.08 % 0.07 %

+0.74 (+0%)

USD 7.80B
VCSH Vanguard Short-Term Corpo.. 0.08 % 0.07 %

+0.16 (+0%)

USD 35.77B
SCHZ Schwab U.S. Aggregate Bon.. 0.01 % 0.04 %

+0.14 (+0%)

USD 7.53B
BLV Vanguard Long-Term Bond I.. 0.00 % 0.07 %

+0.66 (+0%)

USD 6.22B
DTN 0.00 % 0.38 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+1.08 (+0%)

USD 5.45B
JDIV 0.00 % 0.12 %

N/A

N/A
AIIQ 0.00 % 0.79 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
INAU 0.00 % 0.00 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

-0.23 (0%)

USD 1.25M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.23 (0%)

USD 1.25M
SICK 0.00 % 0.95 %

N/A

N/A
YLD Principal Active High Yie.. 0.00 % 0.65 %

+0.07 (+0%)

USD 0.17B
UDVD:LSE SPDR® S&P US Dividend Ar.. 0.00 % 0.00 %

+0.79 (+0%)

USD 2.77B
USDV:LSE SPDR S&P US Dividend Aris.. 0.00 % 0.00 %

+0.59 (+0%)

USD 3.76B
XUKS:LSE db x-trackers FTSE 100 Sh.. 0.00 % 0.00 %

+0.43 (+0%)

USD 8.59M
SPYD:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.00 %

+1.25 (+0%)

USD 4.27B
SPPD:XETRA SPDR® S&P US Dividend Ar.. 0.00 % 0.00 %

+0.09 (+0%)

USD 0.13B
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
ABEQ Absolute Core Strategy ET.. 0.00 % 0.00 %

+0.47 (+0%)

USD 0.08B
SPPD:F SSGA SPDR ETFs Europe I p.. 0.00 % 0.00 %

+0.11 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.74% 44% F 41% F
Dividend Return 1.14% 67% D+ 35% F
Total Return 10.88% 44% F 39% F
Trailing 12 Months  
Capital Gain 12.97% 50% F 84% B
Dividend Return 2.31% 100% F 45% F
Total Return 15.28% 50% F 83% B
Trailing 5 Years  
Capital Gain 57.05% 27% F 83% B
Dividend Return 13.43% 86% B+ 51% F
Total Return 70.48% 36% F 83% B
Average Annual (5 Year Horizon)  
Capital Gain 6.93% 29% F 60% D-
Dividend Return 9.11% 29% F 60% D-
Total Return 2.18% 86% B+ 54% F
Risk Return Profile  
Volatility (Standard Deviation) 8.75% 100% F 89% A-
Risk Adjusted Return 104.11% 64% D 94% A
Market Capitalization 101.99B 95% A 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.40 50% 23%
Price/Book Ratio 2.67 62% 33%
Price / Cash Flow Ratio 0.00 64% 46%
Price/Free Cash Flow Ratio 0.00 64% 36%
Management Effectiveness  
Return on Equity 9.21% 76% 57%
Return on Invested Capital N/A N/A N/A
Return on Assets 4.54% 71% 70%
Debt to Equity Ratio 48.86% 65% 65%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.